Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (252)	8/22/1999 2:00:00 PM
From: WTDEC	Respond to of 666

Peter, news is out. Score another for V1...>) Coulter Pharmaceutical and SmithKline Beecham Announce Priority Review Status for Bexxar Business Wire - July 22, 1999 06:19 SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--July 22, 1999-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR) and SmithKline Beecham (NYSE:SBH) today announced that Bexxar(TM) (tositumomab, iodine I 131 tositumomab) has been assigned priority review status by the U.S. Food and Drug Administration. Priority review status indicates that the license application for Bexxar will be reviewed and action taken by the agency within six months from the June 30, 1999 date of submission. If approved, Bexxar could be the first radioimmunotherapy to become commercially available. "We are delighted to receive priority review status for Bexxar," said Michael F. Bigham, president and chief executive officer of Coulter. "It underscores the FDA's commitment to expeditiously review our license application. Snip> Best regards, Walter

To: Biomaven who wrote (252)	8/22/1999 5:42:00 PM
From: WTDEC	Respond to of 666

Peter, sorry about the prior post...I messed up and thought it was a new release dated August 22, today, rather than the actual date of July 22. :-(

To: Biomaven who wrote (252)	8/23/1999 3:15:00 AM
From: Gordon James	Read Replies (1) \| Respond to of 666

Peter, Thanks for the welcome! I've enjoyed following your posts and interests as a longtime lurker, will enjoy opportunity to interact. Nice lymphoma site that you posted, answers my question. Seems they're paying more attention to keeping the clinical trial info updated on their website than is CLTR. I'm also experiencing problems getting to the CLTR website, unable to access the site right now. Wonder if they pulled the sie over the weekend 'cause some SI agitators were questioning the completeness of data there... ;-) I wonder if you or some other fine citizen here might be so kind as to answer an SI newbie question - how is it that you get italics or other font niceties into your posts? My initial attempts so far have been futile, tried copying text from MS-Word into SI on IE5 browser and the only special feature I got was some garbled characters (quotes and dashes transformed into question marks), without the desired italics being preserved... TIA, Regards, Gordon